2024-12-20 - CoA - Alexion v. Samsung - UPC_CoA_402/2024

Aktenzeichen:
UPC_CoA_402/2024
Datum:
Spruchkörper:
Court of Appeal - Luxembourg (LU)
Art:
Appeal Decision
Parteien:
Alexion Pharmaceuticals, Inc. v. Samsung Bioepis NL B.V.

Kernaussage: 1.

2024-12-20 - CoA - Alexion v. Samsung - UPC_CoA_402/2024
🏛️Court of Appeal - Luxembourg (LU)• Appeal Decision
📅2024-12-20
🔢UPC_CoA_402/2024
Parteien & Vertreter
Kläger / Berufungsführer
Alexion Pharmaceuticals, Inc.
Elena HENNECKE
Beklagter / Berufungsbeklagter
Samsung Bioepis NL B.V.
Peter MEYER
📋ORD_60219/2024
⚖️Appeal RoP220.1
🌐English

1. A linguistic error, a spelling mistake or any other inaccuracy in a patent claim can only be corrected by way of interpretation of the patent claim if the existence of an error and the precise way to correct it are sufficiently certain to the average skilled person on the basis of the patent claim, taking into account the description and the drawings and using common general knowledge. 2. The patent claim must be interpreted from the perspective of the person skilled in the art. The applicant’s assertions during the grant proceedings, and in particular the TBA’s endorsement thereof, can be seen as an indication of the view of the person skilled in the art at the filing date.

The Court of Appeal rejected an appeal against the dismissal of an application for provisional measures due to doubts regarding the patent's validity. The Court confirmed the CFI's decision and explained the legal standard regarding claim interpretation, in particular with regard to alleged errors in a patent claim. The same decision was issued in parallel proceedings against a different party.
Stichwörter
Patent claim interpretation, Appeal, Provisional measures, Error in a patent claim

Nichtigkeitsgründe

Art. 138 EPC
1 Grund
Insufficiency of Disclosure
Art. 83 EPC · Art. 138(1)(b) EPC
Patent invalid (this ground)
“Claim 2, construed to include the signal peptide, is more likely than not insufficiently disclosed; Alexion itself concedes the complete SEQ ID NO: 4 antibody does not bind C5 [48].”
Feststellungen aus Sicht des Patentinhabers bezeichnet. Quelle: KI-Klassifikation (AI)

Entscheidung teilen

Weitere Navigation
Entscheidungen
Rechtstexte
Analysen

Zu Sammlung hinzufügen

0 Einträge hinzufügen zu:

Anmeldung

Registrieren